Current treatment options in multiple sclerosis

  • Adrienne Boissy
  • Robert J. Fox


Multiple Sclerosis Mitoxantrone Progressive Multifocal Leukoencephalopathy Alemtuzumab Natalizumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Hohlfeld R:Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.Brain, 1997, 120:865–916.PubMedCrossRefGoogle Scholar
  2. 2.
    Of importance Antel J, Bar-Or A:Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment.J Neuroimmunol 2006, 180:3–8. The review summarizes the current knowledge of B-cell involvement in MS.PubMedCrossRefGoogle Scholar
  3. 3.
    Trapp BD, Peterson J, Ransohoff RM, et al.:Axonal transection in the lesions of multiple sclerosis.N Engl J Med 1998, 338:278–285.PubMedCrossRefGoogle Scholar
  4. 4.
    Peterson JW, Bèo L, Mèork S, et al.:Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.Ann Neurol 2001, 50:389–400.PubMedCrossRefGoogle Scholar
  5. 5.
    Lucchinetti C, Brèuck W, Parisi J, et al.:Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.Ann Neurol 2000, 47:707–717.PubMedCrossRefGoogle Scholar
  6. 6.
    McDonald WI, Compston A, Edan G, et al.:Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis.Ann Neurol 2001, 50:121–127.PubMedCrossRefGoogle Scholar
  7. 7.
    Of major importance Polman CH, Reingold SC, Edan G, et al.:Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”.Ann Neurol 2005, 58:840–846. Outlines the current standard diagnostic criteria for relapsing and progressive MS.PubMedCrossRefGoogle Scholar
  8. 8.
    Dalton CM, Brex PA, Miszkiel KA, et al.:Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis Ann Neurol 2002, 52:47–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Langer-Gould A, Popat RA, Huang SM, et al.:Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis.Arch Neurol 2006, 63:1686–1691.PubMedCrossRefGoogle Scholar
  10. 10.
    Confavreux C, Vukusic S, Moreau T, et al.:Relapses and progression of disability in multiple sclerosis.N Engl J Med 2000, 343:1430–1438.PubMedCrossRefGoogle Scholar
  11. 11.
    Jacobs LD, Beck RW, Simon JH, et al.:The effect of initiating interferon beta-1a therapy during a first demyelinating event on the development of clinically definite multiple sclerosis.N Engl J Med 2000, 343:898–904.PubMedCrossRefGoogle Scholar
  12. 12.
    Comi G, Filippi M, Barkhof F, et al.:Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.Lancet 2001, 357:1576–1582.PubMedCrossRefGoogle Scholar
  13. 13.
    Kappos L, Polman CH, Freedman MS, et al.:Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.Neurology 2006, 67:1242–1249.PubMedCrossRefGoogle Scholar
  14. 14.
    Jacobs LD, Cookfair DL, Rudick RA, et al.:Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.Ann Neurol 1996, 39:285–294.PubMedCrossRefGoogle Scholar
  15. 15.
    Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.Lancet 1998, 352:1498–1504.Google Scholar
  16. 16.
    Of major importance Polman CH, O’Connor PW, Havrdova E, et al.:A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N Engl J Med 2006, 354:899–910. This study describes the phase III trial results of natalizumab in relapsing MS.PubMedCrossRefGoogle Scholar
  17. 17.
    Hartung HP, Gonsette R, Kèonig N, et al.:Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.Lancet 2002, 360:2018–2025.PubMedCrossRefGoogle Scholar
  18. 18.
    Panitch H, Miller A, Paty D, et al.:Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.Neurology 2004, 63:1788–1795.PubMedGoogle Scholar
  19. 19.
    Cohen JA, Cutter GR, Fischer JS, et al.:Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.Neurology 2002, 59:679–687.PubMedGoogle Scholar
  20. 20.
    Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS,Lancet 1998, 352:1491–1497.Google Scholar
  21. 21.
    Cohen JA, Antel JP:Does interferon beta help in secondary progressive MS? Neurology 2004, 63:1768–1769.PubMedGoogle Scholar
  22. 22.
    Of major importance Kappos L, Weinshenker B, Pozzilli C, et al.:Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.Neurology 2004, 63:1779–1787. This report evaluates how two trials of the same interferon preparation observed very different resultsPubMedGoogle Scholar
  23. 23.
    Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis study Group and the University of British Columbia MS/MRI Analysis Group.Neurology 1996, 47:889–894.Google Scholar
  24. 24.
    Rudick RA, Simonian NA, Alam JA, et al.:Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis.Neurology 1998, 50:1266–1272.PubMedGoogle Scholar
  25. 25.
    Francis GS, Rice GP, Alsop JC:Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.Neurology 2005, 65:48–55. This paper demonstrated the deleterious impact of NAbs on the effect of interferon β-1a treatment.PubMedCrossRefGoogle Scholar
  26. 26.
    Sorensen PS, Koch-Henriksen N, Ross C, et al.:Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.Neurology 2005, 65:33–39.PubMedCrossRefGoogle Scholar
  27. 27.
    CTCS Taskforce:Changing Therapy in Relapsing Multiple Sclerosis: Considerations and Recommendations of a Task Force of the National Multiple Sclerosis Society. New York: National Multiple Sclerosis Society; 2004.Google Scholar
  28. 28.
    Panitch H, Goodin DS, Francis G, et al.:Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial.Neurology 2002, 59:1496–1506.PubMedGoogle Scholar
  29. 29.
    Rask C, Unger E, Walton M:Comparative Study of Rebif to Avonex and Orphan Exclusivity. Rockville, MD: Center for Biologics Evaluation and Research, Food and Drug Administration; 2002.Google Scholar
  30. 30.
    Hernan MA, Olek MJ, Ascherio A:Cigarette smoking and incidence of multiple sclerosis.Am J Epidemiol 2001, 154:69–74.PubMedCrossRefGoogle Scholar
  31. 31.
    Hernan MA, Jick SS, Logroscino G, et al.:Cigarette smoking and the progression of multiple sclerosis.Brain 2005, 128:1461–1465.PubMedCrossRefGoogle Scholar
  32. 32.
    Zhang SM, Hernan MA, Olek MJ, et al.:Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women.Neurology 2001, 57:75–80.PubMedGoogle Scholar
  33. 33.
    Munger KL, Zhang SM, O’Reilly E, et al.:Vitamin D intake and incidence of multiple sclerosis.Neurology 2004, 62:60–65.PubMedGoogle Scholar
  34. 34.
    Munger KL, Levin LI, Hollis BW, et al.:Serum 25-hydroyvitamin D levels and risk of multiple sclerosis.JAMA 2006, 296:2832–2838.PubMedCrossRefGoogle Scholar
  35. 35.
    Mostert S, Kesselring J:Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis.Mult Scler 2002, 8:161–168.PubMedCrossRefGoogle Scholar
  36. 36.
    Romberg A, Virtanen A, Ruutiainen J, et al.:Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study.Neurology 2004, 63:2034–2038.PubMedGoogle Scholar
  37. 37.
    Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.Neurology 1995, 45:1277–1285.Google Scholar
  38. 38.
    Johnson KP, Brooks BR, Cohen JA, et al.:Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial.Neurology 1995, 45:1268–1276.PubMedGoogle Scholar
  39. 39.
    Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J:Doubleblind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS.Neurology 1998, 51:529–534.PubMedGoogle Scholar
  40. 40.
    Keegan M, Konig F, McClelland R, et al.:Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.Lancet 2005, 366:579–582.PubMedCrossRefGoogle Scholar
  41. 41.
    Krapf H, Morrissey SP, Zenker O, et al.:Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.Neurology 2005, 65:690–695.PubMedCrossRefGoogle Scholar
  42. 42.
    Lynn D, Blum W, Cataland S, et al.:Multiple, sclerosis and mitoxantrone treatment-related leukemia: a single center experience.Neurology 2006, 66:A31.Google Scholar
  43. 43.
    Le Page E, Leray E, Chaperon J, et al.:5-year follow-up after mitoxantrone treatment start: an observational study of 100 consecutive patients with aggressive relapsing remitting multiple sclerosis.Neurology 2006, 66:A33.CrossRefGoogle Scholar
  44. 44.
    Of major importance Rudick RA, Stuart WH, Calabresi PA, et al.:Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.N Engl J Med 2006, 354:911–923. This study demonstrated efficacy of natalizumab in patients suboptimally responding to interferon therapy.PubMedCrossRefGoogle Scholar
  45. 45.
    Smith DR, Weinstock-Guttman B, Cohen JA, et al.:A randomized, blinded trial of combination therapy with cyclophosphamide in patients with active MS on interferonbeta.Mult Scler 2005, 11:573–582.PubMedCrossRefGoogle Scholar
  46. 46.
    Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al.:A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis.Neurology, 1999, 52:896–897.Google Scholar
  47. 47.
    Kappos L, Antel J, Comi G, et al.:Oral fingolimod (FTY720) for relapsing multiple sclerosis.N Engl J Med 2006, 355:1124–1140.PubMedCrossRefGoogle Scholar
  48. 48.
    O’Connor PW, Li D, Freedman MS, et al.:A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.Neurology 2006, 66:894–900.PubMedCrossRefGoogle Scholar
  49. 49.
    Jonsson, S, Andersson G, Fex T, et al.:Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.J Med Chem 2004, 47:2075–2088.PubMedCrossRefGoogle Scholar
  50. 50.
    Polman C, Barkhof F, Sandberg-Wollheim M, et al.:Treatment with laquinimod reduces development of active RMI lesions in relapsing MS.Neurology 2005, 64:987–991.PubMedGoogle Scholar
  51. 51.
    Romine JS, Sipe JC, Koziol JA, et al.:A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.Proc Assoc Am Physicians 1999, 111:35–44.PubMedCrossRefGoogle Scholar
  52. 52.
    Brousil JA, Roberts RJ, Schlein AL:Cladribine: an investigational immunomodulatory agent for multiple sclerosis.Ann Pharmacother 2006, 40:1814–1821.PubMedCrossRefGoogle Scholar
  53. 53.
    Coles AJ, Cox A, Le Page E, et al.:The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.J Neurol 2006, 253:98–108.PubMedCrossRefGoogle Scholar
  54. 54.
    Fox E, Coles A, Margolin D, et al.:Immune thrombocytopenic purpura following treatment of multiple sclerosis patients with alemtuzumab in CAMMS223: case reports and risk management plan implementation.Mult Scler 2006, 12:P800.Google Scholar
  55. 55.
    Kappos L, Miller D, MacManusDG, et al.:BGooo12, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis.Mult Scler 2006, 12:S85.Google Scholar
  56. 56.
    Warren KG, Catz I, Ferenczi LZ, et al.:Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.Eur J Neurol 2006, 13:887–895.PubMedCrossRefGoogle Scholar
  57. 57.
    Hellings N, Raus J, Stinissen P:T-cell vaccination in multiple sclerosis: update on clinical application and mode of action.Autoimmun Rev 2004, 3:267–275.PubMedCrossRefGoogle Scholar
  58. 58.
    Krupp LB, MacAllister WS:Treatment of pediatric multiple sclerosis.Curr Treat Options Neurol 2005, 7:191–199.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Mellen Center for Multiple SclerosisClevelandUSA

Personalised recommendations